DEXA is well evidenced for the thing nobody sells it for
Bone density scanning carries a guideline recommendation and moderate net benefit in older women. Premium programmes sell it as a body composition readout, which is a different test with a different evidence base.
DEXA is one of the few tests in a premium health programme with a formal guideline recommendation behind it. It is also, in that setting, almost always sold for a purpose the guideline says nothing about. Both of those statements are worth unpacking, because the gap between them is where the money goes.
The well-evidenced use
The US Preventive Services Task Force recommends bone mineral density screening by DEXA for all women aged 65 and over, and for postmenopausal women under 65 who carry one or more osteoporosis risk factors, finding moderate net benefit in both groups.1 The recommendation was strengthened to specify DEXA on the basis of new evidence reported across 28 publications.2
That is about as good as preventive testing gets: a named modality, a defined population, a stated magnitude of benefit, and a route from the result to a treatment that reduces fractures.
For men, the Task Force found insufficient evidence to recommend for or against.1 This is frequently misreported as men not needing bone scans. It means population screening is unproven in men, not that an individual man with glucocorticoid exposure or a prior fragility fracture should not be scanned.
The number is weaker than it looks
One nuance in the evidence deserves more attention than it gets, because it changes how a normal result should be read.
Bone density is an important fracture risk factor. Age is a stronger one. Older adults fracture at much higher rates than younger adults with identical bone mineral density, because bone quality declines independently of density and the probability of falling rises.4
The practical consequence: a BMD figure in isolation is not a fracture probability. The Task Force points to fracture risk assessment tools such as FRAX, which combine density with age and clinical factors to produce a ten-year probability of a major osteoporotic event.1 A programme handing over a T-score with no risk assessment around it has given you an input rather than an answer.
A reassuring T-score in a 70-year-old who falls is not reassurance.
The use it is actually sold for
Walk into a premium longevity programme and DEXA is rarely presented as osteoporosis screening. It is presented as body composition: fat mass, lean mass, visceral adipose tissue, regional distribution, a percentage to track.
On measurement quality that is a reasonable thing to sell. DEXA is precise, reproducible, and treated as a practical reference standard for body composition outside research settings. Precision is not the problem.
The problem is that no outcome evidence supports the use. Nobody has tested whether a healthy adult who tracks body fat percentage by DEXA every six months ends up healthier than one who uses a tape measure, a set of scales and a mirror. The measurement is better. Whether the better measurement produces a better decision is untested, and for most people the decisions available at that level of resolution are the same decisions available without it.
There is a narrower case where it clearly earns its place. Somebody in a deliberate body recomposition programme, particularly while losing weight on a GLP-1 agonist, has a real question that scales cannot answer: how much of what I am losing is muscle. DEXA answers that, the answer changes the protein and resistance training prescription, and the change has its own evidence. That is a legitimate purchase with a defined question behind it.
Why grade B
Grade B means consistent evidence of benefit from trials with surrogate endpoints, single trials, or strong longitudinal cohorts. Bone density screening in the recommended population sits there comfortably, supported by a formal recommendation with moderate stated net benefit and a clear treatment pathway.
It does not reach A because the chain from screening to fracture reduction runs through treatment decisions rather than a direct randomised test of screening itself, and because the benefit is confined to defined groups rather than adults generally.
Following our own rule that a grade applies to a test for a stated purpose in a stated population, this B covers bone density screening in women 65 and over and in postmenopausal women under 65 with risk factors. It does not cover serial body composition tracking in healthy adults, which would be graded C on current evidence: precise, plausible, and untested against an outcome.
What to ask a programme offering it
Whether the report includes a FRAX or equivalent fracture risk assessment rather than a T-score alone. Whether you are in a population where bone density screening is recommended, and if not, what question the scan is answering instead. And whether it is being sold to you as bone health or as body composition, because the two share a machine and nothing else.
What would change the grade
For the bone density use, a randomised trial of screening against no screening with fracture as the endpoint would move it toward A, though the ethics of withholding a recommended test now make that unlikely to happen.
For body composition, the tractable question is simpler and nobody has run it: randomise adults in a recomposition programme to DEXA-guided against scale-guided monitoring, and measure lean mass retention at a year.
Questions this article answers
- Is a DEXA scan worth it?
- For bone density in the recommended population, yes: the USPSTF finds moderate net benefit for women 65 and over, and for postmenopausal women under 65 with a risk factor. For body composition tracking in a healthy adult, the scan measures precisely but no outcome evidence supports repeating it. Those are two different purchases that happen to use the same machine.
- Who should get a bone density scan?
- All women aged 65 and over, and postmenopausal women under 65 who have at least one osteoporosis risk factor such as low body weight, smoking, prior fracture, glucocorticoid use, parental hip fracture or excess alcohol. For men the USPSTF found insufficient evidence to recommend for or against screening, which does not mean men never need it, only that population screening is unproven for them.
- Is DEXA accurate for body fat percentage?
- It is precise and reproducible, and generally treated as a practical reference standard outside research settings. Precision is not the issue. The open question is whether knowing your body fat percentage to a decimal place, and watching it move, leads to a better outcome than the cheaper measurements you would otherwise use. No trial has tested that.
- Does a good bone density result mean I will not fracture?
- No, and this is the most misread part of the result. Age is a stronger determinant of fracture than bone density: older adults fracture at much higher rates than younger adults with the same BMD, because bone quality declines with age and falls become more likely. A BMD number belongs inside a fracture risk assessment such as FRAX rather than standing on its own.
- US Preventive Services Task Force. Screening for osteoporosis to prevent fractures: recommendation statement.
- USPSTF boosts DEXA in osteoporosis screening. AuntMinnie.
- US Preventive Services Task Force. Screening for osteoporosis: evidence summary.
- Screening for osteoporosis. NCBI Bookshelf, introduction and background.
- Dual energy X-ray absorptiometry scanning for osteoporosis detection: analysis of patients at a tertiary care hospital.
More from Baseline
Claim check: “our patients reversed their biological age by six years”
A recurring line in longevity clinic marketing, and a clean worked example of how a defensible measurement becomes an indefensible statement.
Neko Health alternatives: what to do about a 100,000-person waitlist
Neko built the best-designed cheap health check in Europe and cannot serve the demand. Wait times run six to twelve months. Here is what the alternatives actually replace, and what none of them do.
The cancer blood test finally has a big trial. Read the sensitivity number twice.
PATHFINDER 2 put Galleri through 35,878 people and produced the strongest evidence any multi-cancer blood test has. It also showed the test misses about six in ten cancers, and both facts are compatible with it being useful.